本文關(guān)鍵詞： 烏龍丹 來(lái)氟米特 痰瘀痹阻 類風(fēng)濕關(guān)節(jié)炎　出處：《黑龍江中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：通過(guò)對(duì)比烏龍丹聯(lián)合來(lái)氟米特與旭痹片聯(lián)合來(lái)氟米特兩種治療方案治療痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎的療效差異,從而評(píng)價(jià)烏龍丹聯(lián)合來(lái)氟米特對(duì)痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎的治療效果。方法：篩選60例符合本課題研究方案的痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎患者,經(jīng)醫(yī)院倫理委員會(huì)批準(zhǔn),按照1：1比例,隨機(jī)分為治療組(烏龍丹聯(lián)合來(lái)氟米特)30例,與對(duì)照組(旭痹片聯(lián)合來(lái)氟米特)30例,兩組治療周期均為12周。治療前,經(jīng)統(tǒng)計(jì)學(xué)分析,兩組患者在性別、年齡、病程等方面具有可比性。觀察并記錄第0、12周患者疼痛評(píng)價(jià)、關(guān)節(jié)評(píng)價(jià)(壓痛數(shù)與腫脹數(shù))、患者對(duì)疾病活動(dòng)性評(píng)價(jià)、醫(yī)生對(duì)疾病活動(dòng)性評(píng)價(jià)、體力功能的評(píng)價(jià)、急性期反應(yīng)物水平等指標(biāo),用以評(píng)價(jià)ACR20標(biāo)準(zhǔn)的達(dá)標(biāo)情況；觀察并記錄第0、12周患者關(guān)節(jié)疼痛程度、關(guān)節(jié)腫脹程度、關(guān)節(jié)壓痛程度、屈伸不利、汗出、畏惡風(fēng)寒、腰膝酸軟、晨僵時(shí)間等指標(biāo),用以評(píng)價(jià)中醫(yī)證候療效情況；監(jiān)測(cè)第0、4、8、12周時(shí)血、尿常規(guī),肝、腎功能等安全性指標(biāo)及可能出現(xiàn)的不良反應(yīng)。采用ACR20、50、70標(biāo)準(zhǔn)及中醫(yī)證候療效判定標(biāo)準(zhǔn)作為療效評(píng)價(jià)標(biāo)準(zhǔn)。用以評(píng)價(jià)烏龍丹聯(lián)合來(lái)氟米特對(duì)痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎的治療效果。結(jié)果：1疾病療效評(píng)價(jià)：治療組ACR70達(dá)標(biāo)1例、ACR50達(dá)標(biāo)10例、ACR20達(dá)標(biāo)15例,ACR20未達(dá)標(biāo)4例,總有效率為86.67%；對(duì)照組ACR70達(dá)標(biāo)0例、ACR50達(dá)標(biāo)6例、ACR20達(dá)標(biāo)13例,ACR20未達(dá)標(biāo)11例,總有效率為63.33%。治療組優(yōu)于對(duì)照組。2中醫(yī)證候療效評(píng)價(jià)：治療組臨床控制2例、顯效11例、有效15例、無(wú)效2例,總有效率為93.33%；對(duì)照組臨床控制0例、顯效6例、有效16例、無(wú)效8例,總有效率73.33%。治療組優(yōu)于對(duì)照組。3 ACR20標(biāo)準(zhǔn)各項(xiàng)指標(biāo)比較：在改善患者疼痛評(píng)價(jià)(VAS-1)、關(guān)節(jié)評(píng)價(jià)(壓痛數(shù)與腫脹數(shù))、患者對(duì)疾病活動(dòng)性評(píng)價(jià)(VAS-2)、醫(yī)生對(duì)疾病活動(dòng)性評(píng)價(jià)(VAS-3)、體力功能的評(píng)價(jià)(HAQ)、急性期反應(yīng)物水平(ESR/CRP)等指標(biāo)方面,治療組優(yōu)于對(duì)照組。4中醫(yī)各癥候評(píng)分比較：在改善關(guān)節(jié)疼痛程度、關(guān)節(jié)腫脹程度、關(guān)節(jié)壓痛程度、關(guān)節(jié)屈伸不利、汗出、畏惡風(fēng)寒、腰膝酸軟、晨僵時(shí)間等指標(biāo)方面,治療組優(yōu)于對(duì)照組。結(jié)論：烏龍丹聯(lián)合來(lái)氟米特治療痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎,在臨床總體療效,改善患者癥狀、體征及急性期反應(yīng)物水平(ESR/CRP)等方面效果顯著,優(yōu)于旭痹片聯(lián)合來(lái)氟米特。
[Abstract]:Objective: to compare the therapeutic effects of Wulongdan combined with leflunomide and Xubi tablet in the treatment of phlegm and stasis obstruction rheumatoid arthritis. To evaluate the therapeutic effect of Wulong Dan combined with leflunomide on rheumatoid arthritis of phlegm and stasis obstruction. Methods: 60 cases of rheumatoid arthritis with phlegm and stasis obstruction were selected. According to the proportion of 1: 1, the patients were randomly divided into treatment group (30 cases with Wulongdan combined with leflunomide) and control group (30 cases with Xubi tablet combined with leflunomide). Before treatment, the two groups were comparable in sex, age, course of disease and so on. The pain evaluation of patients at week 0 was observed and recorded. Evaluation of joint (tenderness and swelling), patients' evaluation of disease activity, doctors' evaluation of disease activity, physical function evaluation, acute reaction level and other indicators. To evaluate the standard of ACR20; To observe and record the degree of joint pain, joint swelling, joint tenderness, unfavorable flexion and extension, perspiration, dread of wind and cold, weakness of waist and knee, time of morning stiffness and so on. To evaluate the curative effect of TCM syndrome; Blood, urine routine, liver and kidney function and possible adverse reactions were monitored at the 12th week of the 4th week. ACR2050 was used. To evaluate the therapeutic effect of Wulong Dan combined with leflunomide in treating rheumatoid arthritis of phlegm and stasis obstruction type. Results the curative effect of Wulong Dan combined with leflunomide on rheumatoid arthritis of phlegm and stasis obstruction type was evaluated. In the treatment group, ACR70 reached the standard in 1 case. The total effective rate of ACR50 was 86.67 with 10 cases of ACR20 meeting the standard of 15 cases of ACR20 and 4 cases of failing to reach the standard of ACR20. In the control group, 0 cases of ACR70 were up to standard and 6 cases of ACR50 were up to standard. 13 cases of ACR20 failed to reach the standard of ACR20 in 11 cases. The total effective rate was 63.33. The therapeutic effect of the treatment group was better than that of the control group (2 cases, 11 cases, 15 cases, 2 cases), and the total effective rate was 93.33%. In the control group, there were 0 cases of clinical control, 6 cases of remarkable effect, 16 cases of effective and 8 cases of ineffective. The total effective rate was 73.33.The treatment group was superior to the control group in the comparison of ACR20 criteria: in improving the pain evaluation of patients with VAS-1, the joint evaluation (number of tenderness and swelling). Patients were evaluated for disease activity (VAS-2), doctors for disease activity (VAS-3) and physical function (HAQ). The treatment group was superior to the control group in comparing the scores of TCM symptoms in improving the degree of joint pain, joint swelling and joint tenderness. The treatment group was superior to the control group in terms of joint flexion and extension, perspiration, dread of evil wind and cold, sore waist and knee, time of morning stiffness and so on. Conclusion: Wulong Dan combined with leflunomide in treating rheumatoid arthritis of phlegm and stasis obstruction type. It was better than Xubi tablet combined with leflunomide in general clinical efficacy, improving symptoms, signs and levels of ESR-CRP in acute phase.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R593.22

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王彥峰;張玉英;;從痰瘀痹阻論治特發(fā)性肺纖維化(急性加重)探要[J];實(shí)用中醫(yī)內(nèi)科雜志;2010年10期

2 李敬敏;;通痹益心湯治療痰瘀痹阻型冠心病60例[J];中國(guó)當(dāng)代醫(yī)藥;2010年07期

3 劉維;王朝旭;;從葉天士“久病入絡(luò)”思想辨治類風(fēng)濕關(guān)節(jié)炎痰瘀痹阻證[J];中國(guó)中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志;2012年08期

4 李珊珊;張彥;;中藥外敷治療痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎療效觀察[J];上海針灸雜志;2013年08期

5 周仲瑛;從肝腎虧虛痰瘀痹阻辨治高脂血癥的研究[J];南京中醫(yī)藥大學(xué)學(xué)報(bào);1995年02期

6 唐曉頗;姜泉;胡鏡清;張華東;王海云;烏力吉巴特爾;劉維;谷福順;馮興華;何夏秀;劉宏瀟;王海隆;曹煒;葛琳;;防風(fēng)祛痹丸治療痰瘀痹阻兼氣血兩虛證痛風(fēng)慢性期隨機(jī)對(duì)照雙盲多中心Ⅱ期臨床研究[J];浙江中醫(yī)藥大學(xué)學(xué)報(bào);2012年09期

7 張怡燕;陳進(jìn)春;邱明山;徐振興;;化痰通絡(luò)方治療痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎的臨床觀察[J];中醫(yī)藥通報(bào);2012年01期

8 朱艾莉,張麗艷,閆愛(ài)梅;中醫(yī)治療胸痹痰瘀痹阻型分析[J];實(shí)用醫(yī)技雜志;1995年05期

9 ;文獻(xiàn)文摘[J];中醫(yī)文獻(xiàn)雜志;1996年03期

10 蔡親發(fā);;活血止痛消痹湯治療痰瘀痹阻型痹證的臨床療效[J];內(nèi)蒙古中醫(yī)藥;2014年19期

相關(guān)重要報(bào)紙文章 前1條

1 趙和平;鹿鱉壯督湯[N];中國(guó)中醫(yī)藥報(bào);2010年

相關(guān)碩士學(xué)位論文 前5條

1 閆起;烏龍丹聯(lián)合來(lái)氟米特治療痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎的臨床觀察[D];黑龍江中醫(yī)藥大學(xué);2016年

2 劉寶海;宣痹舒心湯治療冠心病穩(wěn)定型心絞痛（痰瘀痹阻型）的臨床研究[D];黑龍江中醫(yī)藥大學(xué);2008年

3 張怡燕;化痰通絡(luò)方治療痰瘀痹阻型類風(fēng)濕關(guān)節(jié)炎的臨床觀察[D];福建中醫(yī)藥大學(xué);2010年

4 陸丹艷;補(bǔ)腎壯督、祛瘀通絡(luò)法治療強(qiáng)直性脊柱炎腎督虧虛、痰瘀痹阻證的臨床觀察[D];南京中醫(yī)藥大學(xué);2007年

5 孟蕓;間質(zhì)性肺炎痰瘀痹阻型證治規(guī)律及方藥研究[D];山東中醫(yī)藥大學(xué);2014年

，

本文編號(hào)：1491946